A phase I, multi-dose study of SGN-40 (anti-huCD40 mAb) in patients with non-Hodgkin's lymphoma
Phase of Trial: Phase I
Latest Information Update: 31 Dec 2014
At a glance
- Drugs Dacetuzumab (Primary)
- Indications Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Seattle Genetics
- 09 Oct 2008 Actual patient number is 50; study end date changed from July to March 2007, as reported by ClinicalTrials.gov.
- 09 Oct 2008 Genentech reported as a trial Sponsor by ClinicalTrials.gov.
- 06 Jun 2008 Final results were reported during an oral presentation at the International Conference on Malignant Lymphoma (ICML).